➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Colorcon
Dow
Moodys
McKesson

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FENOFIBRIC ACID

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Fenofibric Acid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00300430 Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Completed Abbott Phase 3 2006-09-01 The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.
NCT00300456 Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed Abbott Phase 3 2006-03-01 The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + simvastatin combination therapy with ABT-335 and simvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.
NCT00300469 Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed Abbott Phase 3 2006-03-01 The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fenofibric Acid

Condition Name

Condition Name for Fenofibric Acid
Intervention Trials
Healthy 12
Dyslipidemia 5
Mixed Dyslipidemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fenofibric Acid
Intervention Trials
Dyslipidemias 5
Coronary Artery Disease 5
Myocardial Ischemia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fenofibric Acid

Trials by Country

Trials by Country for Fenofibric Acid
Location Trials
United States 13
Korea, Republic of 4
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fenofibric Acid
Location Trials
Illinois 5
North Dakota 2
Florida 2
West Virginia 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fenofibric Acid

Clinical Trial Phase

Clinical Trial Phase for Fenofibric Acid
Clinical Trial Phase Trials
Phase 4 2
Phase 3 5
Phase 1 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fenofibric Acid
Clinical Trial Phase Trials
Completed 17
Terminated 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fenofibric Acid

Sponsor Name

Sponsor Name for Fenofibric Acid
Sponsor Trials
Mutual Pharmaceutical Company, Inc. 6
Abbott 6
AstraZeneca 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fenofibric Acid
Sponsor Trials
Industry 17
Other 5
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Harvard Business School
Boehringer Ingelheim
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.